AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04735705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerviron
Description: Cerviron ovules ® is a class IIb medical device indicated as adjuvant in the treatment of acute and chronic vulvovaginitis of mechanical etiology, caused by changes of vaginal pH and changes of the vaginal flora. It is also used in cervical lesions of mechanical origin as it favors the healing and re-epithelialization processes and reduces the proliferation of endogenous pathogens.
Study NCT04449965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-iodine
Description: This will be performed twice daily for two weeks.
Study NCT04449965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This will be performed twice daily for two weeks.
Study NCT04680767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally.
Study NCT04680767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [¹⁴C]-LY3502970
Description: Administered orally.
Study NCT05139355 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Effects of Oat and Oat Components on Cardiometabolic risk variables
Description: Oat and oat bioactive components consumed as breakfast meal.
Study NCT05139355 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Effects of Oat and Oat Components on Cardiometabolic risk variables
Description: Oat and oat bioactive components consumed as breakfast meal.
Study NCT04658264 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wheat-Barley Composite flour
Description: A combination of wheat and barley flour with 0.5% food grade xanthan gum as replacement for lost gluten, tested for sensory properties, nutrient profile, and rheology
Study NCT05282147 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Neocam
Description: Screening within 72 hours of birth will be completed using the digital imaging device Neocam which painlessly images the eye's reflection firstly to infrared light and then to a brief green light flash.
Study NCT05078983 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CGA-FI (COMPREHENSIVE GERIATRIC ASSESMENT - FRAILITY INDEX)
Description: GERIATRIC ASSESMENT TEST
Study NCT05041556 — intervention group
Intervention type: OTHER
Intervention: Case-control study of clinical outcomes
Description: A case-control questionnaire will be administered at the home of cases and controls
Study NCT05041556 — intervention group
Intervention type: OTHER
Intervention: Case-control study of mortality outcome
Description: A case-control questionnaire will be administered at the home of cases and controls
Study NCT05775601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-LY3950321
Description: 3 millicuries (±1 mCi)
Study NCT05775601 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET Scan
Description: positron emission tomography (PET) scan
Study NCT06340477 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic SNAGs with conventional therapy
Description: Thoracic (T1- T5) SNAGs 3 repetitions x 1 set, 2 days/week Hot pack for 10 minutes Stretching of upper trapezius, levator scapulae, 5 reps x 1 set x 15 sec hold 2 days/week and Pectoralis Major 10 reps x 1 set x 10 sec hold~Strengthening of deep neck flexors and shoulder retractors (rhomboids) 10 reps x 1 set x 10 sec hold 2 days/week 2 days/week
Study NCT06087874 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vivomixx®
Description: The probiotic group participants will receive 1 sachet of probiotic product daily from 36weeks of gestation up to 7th day of postpartum while placebo groups will 1 sachet placebo prepared with the same colour, taste, and packaging with Vivomixx® daily for the same duration of probiotic groups. Vivomixx® is a non-genetically modified (GMO), gluten-free, high potency microbiotic food supplement, containing eight strains (Streptococcus thermophilus DSM24731® / NCIMB 30438, Bifidobacterium breve DSM24732® / NCIMB 30441, Bifidobacterium longum DSM24736® / NCIMB 30435, Bifidobacterium infantis DSM24737® / NCIMB 30436\*, Lactobacillus acidophilus DSM24735® / NCIMB 30442, Lactobacillus plantarum DSM24730® / NCIMB 30437, Lactobacillus paracasei DSM24733® / NCIMB 30439, Lactobacillus delbrueckii subsp. bulgaricus DSM24734® / NCIMB 30440) of live bacteria (450 billion bacteria per sachet).
Study NCT06087874 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A maltose- containing product with a similar phenotype with Vivomixx®.
Study NCT06340477 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: conventional therapy
Description: Hot pack for 10 minutes Stretching of upper trapezius, levator scapulae, 5 reps x 1 set x 15 sec hold 2 days/week and Pectoralis Major 10 reps x 1 set x 10 sec hold~Strengthening of deep neck flexors and shoulder retractors (rhomboids) 10 reps x 1 set x 10 sec hold 2 days/week 2 days/week
Study NCT06372704 — intervention group
Intervention type: DEVICE
Intervention: HIFEM
Description: All patients had a total of 6 sessions lasting 28 minutes, twice a week, sitting on an electromagnetic chair (BTL EMSELLA®, BTL Industries Inc, Boston, MA, USA).
Study NCT05431374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurement Based Care (MBC)
Description: Patients in both groups will receive either open-label paroxetine (10-40mg/day) or open-label mirtazapine (7.5-45mg/day), within the therapeutic dosage range recommended by the US Food and Drug Authority (Paxil -Highlights of Prescribing Medication, 2022; Remeron -Highlights of Prescribing Medication, 2022). Paroxetine, a selective serotonin reuptake inhibitor, is chosen because it has been one of the most commonly prescribed antidepressants, and mirtazapine, an alpha-2 antagonist, is chosen because it has a different mechanism of action. The treating psychiatrists will decide which of the antidepressants and dosages to prescribe, as long as they were within the study's recommended dosage ranges.~patients in the MBC group will receive treatment according to a schedule that includes individualized starting dosages, dosage adjustment, and medication changes to minimize side effects, maximize safety, and optimize the therapeutic benefit for each patient.
Study NCT05431374 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control/Standard-care
Description: Local medical, psychiatric and family medicine services provide routine care according to their clinical judgment and available resources. Standard-care will be ascertained by the participant's treating physician. Research staff will record the nature and intensity of standard-care delivered to each participant. In current practice, MDD patients are not routinely referred for any psychological therapies in Pakistan. Standard-care in Pakistan largely comprises of pharmacotherapy.
Study NCT05742633 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active release technique
Description: Active Release Technique was applied to patient in prone lying, knee flexed at 90. The therapist placed his elbow tip on taut band of piriformis and direct pressure applied, patient wias then asked to do internal rotation of hip, in order to achieve lengthening of the muscle. This was repeated 5-7 times.~A total of 18 sessions was given over a period of 6 weeks (3 sessions per week)
Study NCT05742633 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Self-myofascial release
Description: Patient position in prone lying Therapist was standing beside the patient at the waistline, working on the contralateral side.~Piriformis muscle was located by an imaginary line drawn between the midpoint of the lateral aspect of the sacrum and the greater trochanter. A contact was established in the gluteal area about 3 cm from the sacrum. Patent was guided to use a foam roller followed by a massage ball.~A total of 18 sessions were given over a period of 6 weeks (3 sessions per week)
Study NCT05624164 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateralised microfracture
Description: making microfracture(4 holes with 2mm diameter) at the lateral side of the footprint right after arthroscopy rotator repair.
Study NCT05428852 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative Studies
Study NCT05428852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative Studies
Study NCT05428852 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurocognitive Assessment
Description: NRG-CC
Study NCT05428852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurocognitive Assessment
Description: NRG-CC
Study NCT05428852 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05428852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05428852 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit
Description: Fitbit Activity Tracking
Study NCT05428852 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Fitbit Activity Tracking
Study NCT05428852 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Undergo ketogenic diet
Study NCT05249907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: Stroking (stroking) movement will be performed on the soft tissue parallel to the muscle fibers on the origo and insertion lines. Vaseline will be preferred as an intermediate to increase the lubricity of the instrument. The frequency of patting and friction movements will be 60 repetitions per minute.~Starting from the medial side of the gastrocnemius (calf) muscle in both legs and moving it longitudinally from distal to proximal and from back to distal in a straight line within 20 seconds, for 2.5 minutes. Then this treatment will be applied to the lateral side of the gastrocnemius muscle for 2.5 minutes.
Study NCT06297512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiotherapy, Temozolomide, Doxorubicin
Description: Radiation treatment Concomitant TMZ: 75mg/m2/day per OS for 7 days per week, from the first day of radiotherapy to the last (maximum cumulative dose 3150mg/m2), with possibility of earlier initiation on clinician's judgment.~After 1 month (4-5 weeks ± 7 days) from the end of RT/TMZ treatment they will receive:~Adjuvant TMZ: 2 cycles at increasing doses (150-180 mg/m2) per OS for 5 consecutive days 28 days apart~After 3 months (12 weeks ± 7 days) from the end of RT/TMZ treatment they will receive:~Dox 4 cycles with 37.5mg/m2/day by continuous infusion over 48 hours (2 days) every 28 days (maximum cumulative dose 300mg/m2)~And after 4 weeks ± 7 days from the end of Dox treatment they will receive:~TMZ adjuvant 12 cycles at increasing doses (150-180 mg/m2) by OS for 5 consecutive days 28 days apart (maximum cumulative dose 16200 mg/m2);
Study NCT05093556 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCHART - Interactive CBT for Headache And Relaxation Training
Description: IVR based cognitive behavioral therapy for headache
Study NCT06555445 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BREATHING EXERCISE
Description: Participants will be guided to adopt a deep breathing practice by emphasizing the use of the diaphragm muscle, thereby minimizing the contribution of accessory muscles during inspiration. This approach fosters the efficiency of respiratory mechanics, aiding in the mitigation of dyspnea symptoms. Participants are directed to undertake these exercises 2-3 times per day, dedicating 15-20 minutes per session, consistently over a period of 2 months. Pursed-Lip Breathing .This technique involves exhaling through semi-closed lips, creating a resistance that helps control the rate of exhalation and, thus, optimizes lung volumes and capacities. This exercise is recommended to be performed similarly to diaphragmatic breathing, 2-3 times daily for 15- 20 minutes per session for a period of 2 months
Study NCT06555445 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BREATHING EXERCISE
Description: Participants will be guided to adopt a deep breathing practice by emphasizing the use of the diaphragm muscle, thereby minimizing the contribution of accessory muscles during inspiration. This approach fosters the efficiency of respiratory mechanics, aiding in the mitigation of dyspnea symptoms. Participants are directed to undertake these exercises 2-3 times per day, dedicating 15-20 minutes per session, consistently over a period of 2 months. Pursed-Lip Breathing .This technique involves exhaling through semi-closed lips, creating a resistance that helps control the rate of exhalation and, thus, optimizes lung volumes and capacities. This exercise is recommended to be performed similarly to diaphragmatic breathing, 2-3 times daily for 15- 20 minutes per session for a period of 2 months
Study NCT06555445 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BREATHING EXERCISE REGIMEN COUPLED WITH BREATHER DEVICE
Description: The resistance on the BREATHER device will be adjusted to match each participant's abilities and progression. The resistance level will be challenging yet manageable, ensuring participant comfort. Each daily session will consist of 15-30 minutes with the BREATHER device and can be split into two shorter sessions if necessary. The total duration of this treatment protocol will span 2 months. The BREATHER device will be employed for both inspiratory and expiratory muscle training. Alongside the device usage, specific breathing exercises, such as diaphragmatic and pursed lip breathing, will be performed
Study NCT04806204 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music therapy
Description: Music therapy will be applied to one group before angiography and to the other group during angiography. Patients who will listen to music before angiography will be offered Turkish Folk, Classical, Turkish Art and Sufi Music as an option, and the music preferred by the patients will be played with headphones for 15-20 minutes. Patients who will listen to music during angiography will be offered Turkish Folk, Classical, Turkish Art and Sufi Music as an option, and the music preferred by the patients will be played through a speaker that will be placed in the angiography hall during the angiography procedure.
Study NCT06229223 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PALOMA
Description: Partnering with Parents of Adolescent Latinos on Mental Health Assistance
Study NCT06415110 — intervention group
Intervention type: DEVICE
Intervention: Allosync Expand
Description: Allosync Expand is used in lumbar posterolateral arthrodesis at 1-3 contiguous levels (L1-S1)
Study NCT06223230 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional psychological interventions and vomit-free management
Description: Nutritional psychological interventions and vomit-free management
Study NCT06444750 — intervention group
Intervention type: OTHER
Intervention: Blood sample collection
Description: Blood sample collection of maximum 70 ml
Study NCT05481801 — intervention group
Intervention type: BIOLOGICAL
Intervention: Covid-19 vaccination
Description: Correct Covid19 vaccination status was considered in the following situation:~Received at least two Covid-19 vaccine doses being the last in the last 6 months.
Study NCT05481801 — intervention group
Intervention type: BIOLOGICAL
Intervention: Influenza vaccination
Description: Correct influenza vaccination status was considered in the following situation:~- Received at least one Influenza vaccine dose in the last year.
Study NCT05481801 — intervention group
Intervention type: BIOLOGICAL
Intervention: Pneumococal vaccination
Description: Correct pneumococal vaccination status was considered if a subject received at least one of the following options:~One pneumococcal conjugate vaccine (PCV) 13 dose in the last year. One PCV13 dose following a pneumococcal polysaccharide vaccine (PPSV) 23 dose between the following 8 weeks and 12 months.~One PPSV 23 dose in the last 5 years. One PPSV23 dose in the last 5 years and a second PPSV23 dose at 5 years or PCV13 at 1 year.
Study NCT05481801 — intervention group
Intervention type: BIOLOGICAL
Intervention: Hepatitis B Virus (HBV) vaccination
Description: Correct Hepatitis B Virus (HBV) vaccination status was considered in the following situation:~.- Received at least three consecutive doses of HBV vaccine during six consecutive months.
Study NCT05315570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BD4QoL platform
Description: The BD4QoL platform consists of a set of services to allow patient monitoring and empowerment, through two main tools: Point of Care application to manage all patients data and follow-up by clinical investigators, and a mobile application (App) installed on participating subject's smartphone. Also, a web-form tool is delivered to allow the QoL questionnaire completion.
Study NCT02699138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone
Description: 100mg of trazodone to be administered orally once.
Study NCT02699138 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Compounded sugar pill
Study NCT02699138 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Epiglottic catheter
Description: Catheter that can be placed through the nose to a position behind the tongue to monitor for upper airway obstruction and to measure changes in pressure below the obstruction.
Study NCT02699138 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epiglottic catheter
Description: Catheter that can be placed through the nose to a position behind the tongue to monitor for upper airway obstruction and to measure changes in pressure below the obstruction.
Study NCT06292949 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistant starch
Description: Constipated patients take 1 pack of resistant starch (20g/pack) daily for 14 days
Study NCT06191055 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta Alanine high dose
Description: 4 intakes of 5 g of beta alanine every 3 hour.
Study NCT06191055 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta Alanine low dose
Description: 4 intakes of 2.5 g of beta alanine every 3 hour.
Study NCT06191055 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: 4 intakes of 2.5 g of wheat semolina every 3 hour.
Study NCT06175377 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention
Description: A percutaneous coronary intervention for chronic total occlusion lesion with at least one implanted coronary stent will be performed as part of routine care.
Study NCT06175377 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Description: A percutaneous coronary intervention for chronic total occlusion lesion with at least one implanted coronary stent will be performed as part of routine care.
Study NCT06175377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Short dual Aspirin/Clopidogrel therapy
Description: Aspirin will be prescribed as part of the patient's normal course of care, according to current recommendations. The second antiplatelet agent will be clopidogrel, the duration of which will vary according to the randomization group of each patient included. Patients will be treated for 1 month.
Study NCT06175377 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Long dual Aspirin/Clopidogrel therapy
Description: Aspirin will be prescribed as part of the patient's normal course of care, according to current recommendations. The second antiplatelet agent will be clopidogrel, the duration of which will vary according to the randomization group of each patient included. Patients will be treated for 6 to 12 months.
Study NCT06175377 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up visit at 1 month
Description: At 1 month following the inclusion a visit or a phone call with the referring cardiologist will be organized.
Study NCT06175377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up visit at 1 month
Description: At 1 month following the inclusion a visit or a phone call with the referring cardiologist will be organized.
Study NCT06175377 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up visit at 6 months
Description: At 6 months following the inclusion a visit or a phone call with the referring cardiologist will be organized.
Study NCT06175377 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up visit at 12 months
Description: At 12 months following the inclusion a visit or a phone call with the referring cardiologist will be organized.
Study NCT05114486 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pilocarpine Ophthalmic administered with the Optejet dispenser
Description: Pilocarpine 2% ophthalmic spray administered with the Optejet dispenser
Study NCT06459713 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: multiplex respiratory polymerase chain reaction test
Description: According to our hospital policy, nasopharyngeal swab samples are collected by the clinicians and transported to the Clinical Microbiology Laboratory of the hospital in 10 minutes. The samples are analyzed in 2 hours and the samples were measured by Thermo Fisher / Applied Biosystems Quant Studio-5 for reverse transcription-polymerase chain reaction (RT-PCR) testing to detect multiplex respiratory agents
Study NCT04691128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: After induction, anesthesia will be maintained with 0.8-1.3 MAC desflurane and 0.05-0.2 μg/kg/min remifentanil.
Study NCT04691128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: After induction, anesthesia will be maintained with 6-8 mg/kg/h propofol and 0.05- 0.2 μg/kg/min remifentanil
Study NCT05114486 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo administered with the Optejet dispenser
Description: Vehicle ophthalmic solution administered with the Optejet dispenser